1996:
(1) Development of TransIT® LT (Low Toxicity) line of transfection products. The breakthrough resulted from the discovery that histone proteins, in conjunction with lipids, serve to increase transfection efficiency while reducing the cellular toxicity associated with cationic lipid mediated transfection.
(2) First demonstration that plasmid DNA could be delivered effectively into liver cells in vivo (mice) using rapid intravascular injections.
1997:
Development of Label IT® non-enzymatic nucleic acid labeling technology. This technology enabled fluorescent labeling and tracking of nucleic acids in cells and tissues.
1998:
First demonstration that plasmid DNA could be delivered effectively into skeletal muscle cells in vivo using rapid intravascular injections.
1999:
(1) First demonstration of high efficiency gene delivery to mouse liver following a rapid injection of plasmid DNA into the tail vein.
(2) First demonstration that “caged” DNA-containing nanoparticles are resistant to aggregation under physiologic salt conditions.
2001:
(1) Development and launch of the first high efficiency transfection reagent, TransIT-TKO® Reagent, designed specifically for siRNA delivery into mammalian cell.
(2) First demonstration of efficient non-viral delivery of genes (plasmid DNA) into primate skeletal muscle.
2002:
First demonstration of siRNA mediated knockdown of an endogenously expressed gene in mice.
2003:
Development of low toxicity, DNA-containing nanoparticles for gene delivery to lungs.
2004:
Development of clinically viable, high efficiency Pathway IV™ method for delivering plasmid DNA into mammalian skeletal muscle.
2005:
Development and launch of a one step, non-enzymatic labeling method for microRNA, the Label IT® miRNA Labeling Kit.
2006:
Development of genetic immunization method in research animals by intravenous delivery
